[go: up one dir, main page]

WO2000021929A1 - Procede de preparation de 4-1h-indole-3-glyoxamides substituees - Google Patents

Procede de preparation de 4-1h-indole-3-glyoxamides substituees Download PDF

Info

Publication number
WO2000021929A1
WO2000021929A1 PCT/US1999/008325 US9908325W WO0021929A1 WO 2000021929 A1 WO2000021929 A1 WO 2000021929A1 US 9908325 W US9908325 W US 9908325W WO 0021929 A1 WO0021929 A1 WO 0021929A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alkyl
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/008325
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nancy Kay Harn
Richard Duane Miller
Edward Francis Plocharczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US09/787,587 priority Critical patent/US6380397B1/en
Priority to EP99917552A priority patent/EP1119549A4/fr
Priority to JP2000575838A priority patent/JP2002527421A/ja
Priority to CA002347718A priority patent/CA2347718A1/fr
Priority to AU35644/99A priority patent/AU3564499A/en
Publication of WO2000021929A1 publication Critical patent/WO2000021929A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to a process for preparing certain lH-indole-3-glyoxamides useful for inhibiting SPLA2 mediated release of fatty acids for conditions such as septic shock and intermediates useful in the preparation of such compounds .
  • Certain lH-indole-3-glyoxamides are known to be potent and selective inhibitors of mammalian ⁇ PLA2 useful for treating diseases, such as septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis and related SPLA2 induced diseases.
  • diseases such as septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis and related SPLA2 induced diseases.
  • EPO publication No. 0675110 discloses such compounds.
  • U.S. Patent No. 3,449,363 describes trifluoromethylindoles having glyoxylamide groups at the 3 position of the indole nucleus.
  • U.S. Patent No. 3,351,630 describes alpha- substituted 3-indolyl acetic acid compounds and their preparation inclusive of glyoxylamide intermediates.
  • U.S. Patent No. 2,825,734 describes the preparation of 3- (2-amino-l-hydroxyethyl) indoles using 3- indoleglyoxylamide intermediates such as l-phenethyl-2- ethyl-6-carboxy-N-propyl-3-indoleglyoxylamide (see, Example 30) .
  • U.S. Patent No. 4,397,850 prepares isoxazolyl indolamines using glyoxylamide indoles as intermediates.
  • U.S. Patent No. 3,801,594 describes analgesics prepared using 3-indoleglyoxylamide intermediates.
  • Conversion to the glyoxamide is achieved by reacting the oc- [ (indol-4-yl) oxy] alkanoic acid ester first with oxalyl chloride, then with ammonia, followed by hydrolysis with sodium hydroxide in methanol .
  • an appropriately substituted propronylacetate is halogenated with sulfuryl chloride.
  • the halogenated intermediate is hydrolyzed and decarboxylated by treatment with hydrochloric acid then reacted with an appropriately substituted cyclohexane dione.
  • Treatment of the alkylated dione with an appropriate amine affords a 4-keto-indole which is oxidized by refluxing in a high-boiling polar hydrocarbon solvent such as carbitol in the presence of a catalyst, such as palladium on carbon, to prepare the 4-hydroxyindole which may then be alkylated and converted to the desired glyoxamide as described above.
  • This process however is limited by the required high temperature oxidation and requires recovery of a precious metal catalyst.
  • the process of the present invention employs a sulfinylation step.
  • sulfinylation reactions employ the use of hydride bases which cause a delayed onset exotherm and the evolution of gas. Such process conditions are undesirable in a commercial setting.
  • Patai The Chemistry of Sulfinic Acids, Esters and Their Derivatives, John Wiley and Sons, 1990, p. 11, teaches a synthesis of sulfinic esters and their salts using a variety of activating agents.
  • the present invention provides an improved process for preparing lH-indole-3-glyoxamides .
  • the process of the present invention can be performed with inexpensive, readily available, reagents under milder conditions and resulting in better overall yield while avoiding the production of furan byproducts.
  • the present process allows for transformation with a wider variety of substituents on the indole platform.
  • the present invention provides a process for preparing a compound of the formula I or a pharmaceutically acceptable salt or prodrug derivative thereof;
  • R 1 is selected from the group consisting of C7-C2 0 alkyl
  • R-LO is selected from the group consisting of halo, -C ] _-C ] _ Q alkyl, -C]_-C]_o (alkoxy) , -S- (C ⁇ _-C]_o) alkyl and halo (C]_-CIQ) alkyl, and t is an integer from 0 to 5 both inclusive;
  • R ⁇ is selected from the group consisting of hydrogen, halo, -C1-C3 (alkyl) , -C3-C4 (cycloalkyl) , -C 3 -C (cyclo- alkenyl), -0 ( C1-C2 ) alkyl, -8(02-02) alkyl, aryl, aryloxy, and HET;
  • R4 is selected from the group consisting of -CO2H, -SO3H, and -P(O) (OH) 2 or salt or prodrug derivatives thereof;
  • R ⁇ is selected from the group consisting of hydrogen, - (C ] _-
  • R 8 is (C]_-Cg) alkyl, aryl or HET; with SO2CI2 to form a compound of formula IX
  • alkylating agent of the formula XCH2R 4a where X is a leaving group and R 4a is -C0 2 R 4b , -S0 3 R 4b , -P(O) (OR 4b ) 2 , or -
  • alkylating agent of the formula XCH2R 4a where X is a leaving group and R a is -C0 2 R 4b , -S0 3 R 4b , -P(O) (OR 4b ) 2 , or
  • alkylating agent of the formula XCH2R a where X is a leaving group and R 4a is -C0 2 R 4b , -S0 3 R 4b , -P(O) (OR 4b ) 2 , or
  • the present invention provides, in addition, novel intermediates of the formula V 1
  • R ⁇ , R ⁇ and R ⁇ are as defined above and R is - (C ⁇ _-Cg) alkyl, aryl or substituted aryl.
  • R is - (C ⁇ _-Cg) alkyl, aryl or substituted aryl.
  • Such compounds are useful in the process of preparing compounds of formula I.
  • the present invention provides a process for preparing compounds of the formula RSOX where R is - (C ⁇ _-Cg) alkyl, aryl or substituted aryl and
  • X is - (C ⁇ _-Cg) alkoxy; comprising treating a compound of the formula
  • R is - (C_-Cg) alkyl, aryl or substituted aryl and M is an alkali metal; with an acid and an alcohol of the formula - (C1-C2) OH.
  • alkyl by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, heptyl, hexyl, octyl, nonyl, decyl, and the like.
  • (C1-C10) alkoxy denotes a group such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, n-pentoxy, isopentoxy, neopentoxyl, heptoxy, hexoxy, octoxy, nonoxy, decoxy and like groups, attached to the remainder of the molecule by the oxygen atom.
  • (C3-C4) cycloalkyl includes cyclopropyl, and cyclobutyl groups
  • C3-C4 cycloalkenyl includes a cyclopropenyl or cyclobutenyl ring having a double bond at the 1- or 2- position.
  • halo means fluoro, chloro, bromo or iodo.
  • halo (Ci-Cio) alkyl means a (Ci-Cio) lkyl group, substituted with from 1 to 3 halo atoms, attached to the remainder of the molecule by the alkyl group.
  • halo (Ci-Cio) lkyl includes the term halo (C2-Cg) alkyl .
  • halo (C ⁇ Cg) alkoxy means a halo- substituted alkoxy group which group is attached to the remainder of the molecule at the oxygen of the alkoxy.
  • aryl means a group having the ring structure characteristic of benzene, pentalene, indene, naphthalene, azulene, heptalene, phenanthrene, anthracene, etc.
  • the aryl group may be optionally substituted with 1 to 3 substituents selected from the group consisting of (C ] _-Cg) alkyl (preferably methyl),
  • aryloxy means an aryl group attached to the remainder of the molecule by an oxygen linker.
  • the term "leaving group” means a substituent with an unshared electron pair that departs from the substrate in a nucleophilic substitution reaction.
  • the term “leaving group” includes halo, sulfonate, acetate and the like.
  • the term HET includes pyridine, pyrazine, pyrimidine, pyridazine, pyrrole, pyrazole, furan, thiophene, thiazole, isothiazole, oxadiazole, thiadiazole, imidazole, triazole and tetrazole.
  • the heterocyclic ring can be attached to the remainder of the molecule by any carbon in the heterocyclic ring.
  • salts of the compounds of formula I are an additional aspect of the invention.
  • various salts may be formed which are more water soluble and physiologically suitable than the parent compound.
  • Representative pharmaceutically acceptable salts include but are not limited to the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin.
  • salts include the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al . , "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).
  • acid protecting group is used herein as it is frequently used in synthetic organic chemistry, to refer to a group which will prevent an acid group from participating in a reaction carried out on some other functional group of the molecule, but which can be removed when it is desired to do so.
  • acid protecting group is discussed by T.W. Greene in chapter 5 of Protective Groups in Organic Synthesis, John Wiley and Sons, New York, 1981, incorporated herein by reference in its entirety.
  • acid protecting groups includes ester or amide derivatives of the acid group, such as methyl, methoxymethyl, methyl-thiomethyl, tetrahydropyranyl, methoxyethoxymethyl, benzyloxymethyl, phenylaryl, ethyl, 2, 2, 2-trichloroethyl, 2-methylthioethyl, t-butyl, cyclopentyl, triphenylmethyl, p-bromobenzyl, trimethylsilyl, N,N-dimethyl, pyrrolidinyl, piperidinyl or o-nitroanilide .
  • a preferred acid-protecting group is methyl.
  • Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo.
  • Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985) .
  • Prodrugs include acid derivatives, such as, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine.
  • Simple aliphatic esters e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl
  • aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs.
  • Other preferred esters include morpholinoethyloxy, diethylglycolamide and diethylaminocarbonylmethoxy .
  • double ester type prodrugs such as (acyloxy) alkyl esters or ( (alkoxycarbonyl) oxy) alkyl esters.
  • a preferred group of compounds of formula I prepared by the process of the instant invention are those wherein:
  • R t is selected from the group consisting of halo, - C 1 -C 10 alkyl, -C ⁇ -C]_o (alkoxy) , -S-(C 1 -C 10) alkyl and halo (C]_-C]_o) alkyl, and t is an integer from 0 to 5 both inclusive;
  • R2 is halo, cyclopropyl, methyl, ethyl, propyl, O-methyl or S-methyl;
  • R 4 is -C0 2 H;
  • R 5 , R 6 and R 7 are H.
  • Preferred compounds of formula V 1 are those wherein
  • R is aryl where R ⁇ O is selected from the group consisting of halo, - (Ci-Cio) alkyl, - (C ⁇ -CIQ) alkoxy, -S (C -C ⁇ o) alkyl and halo (C_-C ] _ Q ) alkyl, and t is an integer from 0 to 5; R2 is selected from the group consisting of halo, cyclopropyl, methyl, ethyl, propyl, O-methyl and S-methyl; and
  • R 5 is H.
  • R is phenyl or tolyl
  • RIO is selected from the group consisting of halo, - (C1-C4) alkyl, - (C1-C4) alkoxy, -S (C1-C ) alkyl and halo (C ⁇
  • R2 is methyl, ethyl or propyl
  • R 5 is H.
  • Preferred substituent groups of compounds of formula ⁇ include the following:
  • R 1 is - ( C 1 -C 1 3 ) al kyl ;
  • R!° is selected from the group consisting of - (C ] _-Cg) alkyl and - (C_-Cg) alkoxy;
  • RIO is selected from the group consisting of -S (C ⁇ -Cg) alkyl and halo (C ] _-Cg) alkyl;
  • (f) t is an integer from 0 to 3, both inclusive;
  • R2 is selected from the group consisting of hydrogen, halo, - (C1-C3) alkyl, and -0 (C]_-Cg) alkyl;
  • R2 is selected from the group consisting of -0(C!-C 2 ) alkyl and -S (C1 . -C2) alkyl;
  • R ⁇ is selected from the group consisting of aryl and aryloxy
  • (k) R5 is selected from the group consisting of hydrogen, (C ] _-Cg) alkyl and (C ⁇ -Cg) alkoxy;
  • R ⁇ is selected from the group consisting of halo (C ⁇ _-Cg) alkoxy and halo (C2 ⁇ Cg) alkyl;
  • R ⁇ is selected from the group consisting of bromo, chloro, fluoro and codo;
  • R" 1 is aryl
  • Compounds which can be made by the process of the instant invention include: ( (3- (2-amino-l, 2-dioxyethyl) -2-methyl-l- (phenylmethyl) -1H- indol-4-yl) oxy) acetic acid; dl-2- ( (3- (2-amino-l, 2-dioxyethyl) -2-methyl-l- (phenylmethyl) ⁇ lH-indol-4-yl) oxy) propanoic acid; (3- (2-amino-l, 2-dioxyethyl) -1- ( ( (1, l'-biphenyl) -2- ylmethyl) -2-methyl-lH-indol-4-yl) oxy) acetic acid; (3- (2-amino-l, 2-dioxyethyl) -1- ( (1,1' -biphenyl) -3-ylmethyl) •
  • preferred compounds include: ( (3- (2-amino-l, 2-dioxyethyl) -2-ethyl-l- (phenylmethyl) -1H- indol-4-yl) oxyacetic acid; ( (-3- (2-amino-l, 2-dioxyethyl) -2-ethyl-6-methyl-l- (phenylmethyl) -lH-indol-4-yl) oxy) acetic acid; ( (-3- (2-amino-l, 2-dioxyethyl) -2, 6-dimethyl-l- (phenylmethyl) - lH-indol-4-yl) oxy) acetic acid; ( (3- (2-amino-l, 2-dioxyethyl) -2-methyl-l- (phenylmethyl) -1H- indol-4-yl) oxy) acetic acid;
  • the most preferred compound which can be prepared by the instant process is ( (3- (2-amino-l, 2-dioxyethyl) -2- ethyl-1- (phenylmethyl) -lH-indol-4-yl) oxyacetic acid or a pharmaceutically acceptable salt thereof.
  • the process of the present invention provides an improved method for synthesizing the compounds of formula I using inexpensive, readily available reagents as shown in Scheme I as follows.
  • Ketone (V) is dissolved in a suitable solvent preferably an aprotic solvent such as toluene.
  • suitable solvents include but are not limited to tetrahydrofuran (THF) , dimethylformamide (DMF), dioxane or acetone.
  • THF tetrahydrofuran
  • DMF dimethylformamide
  • the substrate/solvent solution may be sonicated or heated slightly, if necessary to facilitate dissolution.
  • the amount of solvent used should be sufficient to ensure that all compounds stay in solution until the desired reaction is complete.
  • the solution is treated with a base, preferably an alkoxide base, then with a sulfinating reagent of the
  • R is - (C ⁇ -C 6 ) alkyl, aryl or substituted aryl and X is (C ⁇ C 6 ) alkoxy, halo or -0C0 2 (Cj-C 6 ) alkyl .
  • the sulfinating reagent may be prepared according to the procedure of J.W. Wilt et al . , J. Org. Chem, 1967, 32, 2097.
  • Preferred sulfinating agents include methyl p-tolyl sulfinate, methylbenzene sulfinate or p-toluylsulfinic isobutyric anhydride.
  • Preferred alkoxide bases include methoxide or ethoxide bases of sodium, potassium or lithium. Potassium methoxide is especially preferred.
  • Other suitable bases include but are not limited to sodium hydride, or LDA. Generally, from about 0.75 to 10 equivalents of base relative to the starting material is employed; preferably from about 1 to about 3 equivalents; most preferably about 2 equivalents .
  • the reaction may be conducted at temperatures from about 15°C to reflux, and is substantially complete in from one to 24 hours.
  • Intermediate V 1 can be isolated by conducting the reaction at temperatures of from 15°C to
  • the amount of sulfinating reagent is not critical, however, the reaction is best accomplished using a molar equivalent or excess relative to the pyrrole starting material (V) .
  • V 1 a sulfinating reagent is replaced with a disulfide compound of the formula R 20 SSR 20 -where R 20 is alkyl or aryl.
  • Oxidation of the sulfide intermediate is achieved using an appropriate oxidizing reagent such as hydrogen peroxide or m-chloroperbenzoic acid.
  • Indole (IV) may then be readily alkylated with an alkylating agent of the formula XCH 2 R 4a where X is a suitable leaving group and R 4a is a protected carboxy, sulfonyl or phosphonyl acid group, preferably protected with an ester group, in the presence of a base.
  • Methyl bro oacetate is a preferred alkylating agent.
  • Suitable bases include potassium carbonate, sodium carbonate, lithium carbonate, cesium carbonate, sodium bicarbonate, potassium bicarbonate or potassium hydroxide. Potassium carbonate is preferred.
  • the amount of alkylating agent is not critical, however, the reaction is best accomplished using a molar excess of alkylating agent relative to the starting material.
  • the reaction is preferably carried out in an organic solvent such as acetone, acetonitrile or dimethylformanide.
  • organic solvent such as acetone, acetonitrile or dimethylformanide.
  • suitable solvents include but are not limited to methanol, toluene, tetrahydrofuran, methyl ethyl ketone, acetonitrile, or t-butyl methylether.
  • the reaction is conducted at temperatures of from about 0° to
  • reaction temperature 100°C, preferably at ambient temperature, and is substantially complete in about 1 to 24 hours depending on the reactants employed and such conditions as reaction temperature.
  • phase transfer reagent such as tetrabutylammoniumbromide may be employed.
  • glyoxamide II is readily achieved in a two step process by first treating intermediate III with oxalyl chloride at concentrations from about 0.2 to
  • Solvents such as methylene chloride, chloroform, trichloroethylene, carbon tetrachloride, ether or toluene are preferred. Temperatures from about -20°C to ambient temperature are suitable, preferably about -5°C.
  • the solution is treated with ammonia; either bubbled in as a gas or, preferably, using a molar excess of 30% aqueous ammonia.
  • the reaction is typically conducted at temperatures from about -25°C to 25°C, preferably at about -2°C to 0°C, and is substantially complete in 10 minutes to an hour.
  • Hydrolysis of II is achieved using a base such as potassium hydroxide, lithium hydroxide or sodium hydroxide, preferably sodium hydroxide, in a lower alcohol solvent, such as methanol, ethanol, isopropanol, etc., or solvents such as tetrahydrofuran, dioxane and acetone.
  • a base such as potassium hydroxide, lithium hydroxide or sodium hydroxide, preferably sodium hydroxide
  • a lower alcohol solvent such as methanol, ethanol, isopropanol, etc.
  • solvents such as tetrahydrofuran, dioxane and acetone.
  • intermediates V ⁇ and IV can be isolated.
  • intermediate IV can be isolated by extraction from a solution of IV in a suitable organic solvent, such as toluene, into a solution of a base and a water miscible solvent.
  • the pH of the aqueous layer must initially be greater than 12.
  • the layers are separated and the pH of the aqueous layer is adjusted to a range of from 1 to 12 more preferably 9-11.5 most preferably 11, Intermediate IV is isolated from the aqueous layer, preferably by extraction into an organic solvent in which the intermediate is soluble.
  • the pH of the aqueous layer must initially be greater than 12. Concentrations of base from about 0.5 N to 5N are preferred, more preferably, from about 1.5N to 2.5N. The most preferred concentration of base is 2N.
  • Suitable water-miscible solvents include but are not limited to methanol, acetone, isopropanol, acetonitrile, dioxane or tetrahydrofuran. Methanol is preferred.
  • the order of addition is not critical, preferably the pH of the aqueous solution containing the intermediate is adjusted after addition of the organic solvent into which the intermediate IV is to be extracted.
  • Scheme I (a) illustrates the two pot procedure, described above, for the preparation of intermediate IV.
  • Intermediate V 1 can be isolated and purified using standard chromatographic procedures.
  • Scheme 1(a)
  • V R 8 is (C ⁇ -Cg) alkyl or aryl
  • An appropriately substituted propionylacetate X is first halogenated by treatment with sulfuryl chloride, preferably at equimolar concentrations relative to the starting material, at temperatures of from about 0°C to 25°C, preferably less than 15°C, to prepare IX.
  • Hydrolysis and decarboxylation of IX is achieved by refluxing with an aqueous acid, such as hydrochloric acid, for from about 1 to 24 hours.
  • the solution containing the decarboxylated product VIII is neutralized to adjust the pH to about 7.0-7.5, then reacted with cyclohexanedione VII (preferably at equimolar concentrations) and a base, preferably sodium hydroxide, to yield the triketone onohydrate VI as a precipitate which may be purified and isolated, if desired.
  • the reaction is preferably conducted at temperatures of from -20°C to ambient temperatures and is substantially complete in about 1 to 24 hours.
  • the above reactions are preferably run as a "one pot” process with the reactants added to the reaction vessel in the order given above.
  • the reaction is allowed to proceed without isolating compounds of formula IX or VIII, thus avoiding exposure to these volatile lachrymators .
  • V is achieved by refluxing VI in a high boiling non-polar solvent which forms an azeotrope with water, preferably toluene, with an equimolar quantity of an amine of the formula R ⁇ NH2, where Rl is as defined above.
  • Solvents with a boiling point of at least 100°C are preferred, such as toluene, xylene, cymene, benzene, 1, 2-dichloroethane or mesitylene, thus eliminating the need for a pressure reactor. Sufficient solvent should be employed to ensure that all compounds stay in solution until the reaction is substantially complete in about 1 to 24 hours .
  • sulfinylating reagents RSX may be prepared in an acid catalyzed reaction by reacting an o
  • reaction is preferably conducted at ambient temperatures preferably 15-30°C, more preferably 20-25°C in the alcohol solvent which corresponds to the desired ester product,
  • reaction may be run with an equivalent of the desired alcohol in a suitable aprotic solvent such as toluene. More preferably the reaction is run with an excess of alcohol in solvent; most preferably in neat alcohol which corresponds to the desired ester product
  • the reaction is conducted using a molar excess of acid relative to the sulfinate starting material.
  • Methyl-p toluene sulfinate (1121gms, 6.59moles, 1.65eq) was added and the mixture was heated to 30 C°. After ⁇ 2.5 hrs, the mixture darkened as gas evolution and an exotherm to 47 deg c was observed. TLC indicated complete consumption of starting material. The reaction was then cooled to 0 to 5
  • the compound of preparation 2 (25 g, 77 mmol) was dissolved in 175 mL dichloromethane and the solution was cooled with an ice bath.
  • Oxalyl chloride (7.1 mL, 81 mmol) was added dropwise to maintain the reaction temperature below 35°C. After 30 min, a small amount of starting material was observed so additional oxalyl chloride (0.5 mL, 6 mmol) was added. After 30 min, the reaction was diluted with 175 L dichloromethane and 175 mL water was added. Ammonium hydroxide (22 mL, 309 mmol) ) was diluted with 75 L water and cooled with an ice bath.
  • the cold ammonia solution was added to the reaction mixture dropwise to maintain the reaction temperature below 6°C. At the end of the addition, the reaction mixture was warmed to 30°C to dissolve all solids. After cooling to room temperature, the layers were separated and the organic layer was washed with water. The organic solution was mixed with 15 g activated carbon for 15 minutes. The mixture was filtered through Celite. The filtrate was evaporated to give a yellow solid which was recrystallized from 325 L methanol to give the title product ( (2-ethyl-l- (phenylmethyl) -lH-indol-4-yl) oxy) acetic acid methyl ester as a yellow solid (27.2 g, 89% yield) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation de 1H-indole-3-glyoxamides utilisées pour inhiber SPLA2 et de nouveaux intermédiaires servant à préparer ces composés.
PCT/US1999/008325 1998-10-09 1999-04-15 Procede de preparation de 4-1h-indole-3-glyoxamides substituees Ceased WO2000021929A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/787,587 US6380397B1 (en) 1999-04-15 1999-04-15 Process for preparing 4-substituted-1H-indole-3-glyoxamides
EP99917552A EP1119549A4 (fr) 1998-10-09 1999-04-15 Procede de preparation de 4-1h-indole-3-glyoxamides substituees
JP2000575838A JP2002527421A (ja) 1998-10-09 1999-04-15 ４−置換−１ｈ−インドール−３−グリオキサミドの製造方法
CA002347718A CA2347718A1 (fr) 1998-10-09 1999-04-15 Procede de preparation de 4-1h-indole-3-glyoxamides substituees
AU35644/99A AU3564499A (en) 1998-10-09 1999-04-15 Process for preparing 4-substituted-1h-indole-3-glyoxamides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10360498P 1998-10-09 1998-10-09
US60/103,604 1998-10-09

Publications (1)

Publication Number Publication Date
WO2000021929A1 true WO2000021929A1 (fr) 2000-04-20

Family

ID=22296053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/008325 Ceased WO2000021929A1 (fr) 1998-10-09 1999-04-15 Procede de preparation de 4-1h-indole-3-glyoxamides substituees

Country Status (11)

Country Link
EP (1) EP1119549A4 (fr)
JP (1) JP2002527421A (fr)
AR (1) AR015766A1 (fr)
AU (1) AU3564499A (fr)
CA (1) CA2347718A1 (fr)
CO (1) CO5021230A1 (fr)
DZ (1) DZ2771A1 (fr)
PE (1) PE20000429A1 (fr)
SV (1) SV1999000042A (fr)
TW (1) TW472041B (fr)
WO (1) WO2000021929A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005808A1 (fr) * 2000-07-14 2002-01-24 The University Of Queensland Nouveaux procedes et compositions de traitement ou de prevention de la dysmenorrhee et des effets secondaires menstruels: utilisation d'inhibiteurs de phospholipases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675110A1 (fr) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibiteurs
WO1998037069A1 (fr) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Derives d'acide indoldicarboxylique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032769A (ja) * 1983-08-02 1985-02-19 Sagami Chem Res Center ４−ヒドロキシインド−ル誘導体の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0675110A1 (fr) * 1994-04-01 1995-10-04 Eli Lilly And Company 1H-Indole-3-glyoxylamide sPLA2 inhibiteurs
WO1998037069A1 (fr) * 1997-02-20 1998-08-27 Shionogi & Co., Ltd. Derives d'acide indoldicarboxylique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRAHEIM S. E. ET AL: "Indole Inhibitors of Human Nonpancreatic Secretory Phospoholipase A2. 3. Indole-3-Glyoxamides", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 26, December 1996 (1996-12-01), USA, pages 5159 - 5175, XP002073103 *
See also references of EP1119549A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005808A1 (fr) * 2000-07-14 2002-01-24 The University Of Queensland Nouveaux procedes et compositions de traitement ou de prevention de la dysmenorrhee et des effets secondaires menstruels: utilisation d'inhibiteurs de phospholipases

Also Published As

Publication number Publication date
DZ2771A1 (fr) 2003-12-01
EP1119549A1 (fr) 2001-08-01
CO5021230A1 (es) 2001-03-27
CA2347718A1 (fr) 2000-04-20
TW472041B (en) 2002-01-11
JP2002527421A (ja) 2002-08-27
PE20000429A1 (es) 2000-05-23
AU3564499A (en) 2000-05-01
EP1119549A4 (fr) 2003-01-29
AR015766A1 (es) 2001-05-16
SV1999000042A (es) 2000-04-11

Similar Documents

Publication Publication Date Title
AU750368B2 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
AU735516B2 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6617460B1 (en) Process for preparing toluenesulfinates
US6380397B1 (en) Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6407261B1 (en) Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
WO2000021929A1 (fr) Procede de preparation de 4-1h-indole-3-glyoxamides substituees
US6570023B1 (en) Process for preparing toluenesulfinates
WO2015181507A1 (fr) Nouveaux composes de type 5-acylsulfanyl-histidine en tant que precurseurs des 5-sulfanylhistidines correspondantes et de leurs disulfures
WO1999054295A1 (fr) Process de fabrication de composes 4-hydroxy indole, indazole et carbazole
MXPA00009955A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
CZ20003824A3 (cs) Způsob přípravy 4-substituovaných-lH-indol-3- glyoxamidů
MXPA99011973A (en) Process for preparing 4-substituted-1h-indole-3-glyoxamides
CZ466499A3 (cs) Způsob přípravy v poloze 4-substituovaného derivátu ΙΗ-indol glyoxamidu a meziprodukt pro tuto přípravu
JP2002053552A (ja) ４，６−ジメチルインドール及びその誘導体の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09787587

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999917552

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2347718

Country of ref document: CA

Ref country code: CA

Ref document number: 2347718

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 575838

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999917552

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999917552

Country of ref document: EP